**1. Introduction**

Venoms are the secretion of venomous animals, which are synthesized and stored in specific areas of their body i.e., venom glands. The animals use venoms for defense and/or to immo‐ bilize their prey. Most of the venoms are complex mixture of biologically active compounds of different chemical nature such as multidomain proteins, peptides, enzymes, nucleotides, lipids, biogenic amines and other unknown substances. Venomous animals as snakes, spi‐ ders, scorpions, caterpillars, bees, insects, wasps, centipedes, ants, toads and frogs have largely shown biotechnological or pharmacological applications. During long-term evolu‐ tion, venom composition underwent continuous improvement and adjustment for efficient functioning in the killing or paralyzing of prey and/or as a defense against aggressors or predators. Different venom components act synergistically, thus providing efficiency of ac‐ tion of the components. Venom composition is highly species-specific and depends on many factors including age, sex, nutrition and different geographic regions. Toxins, occurring in venoms and poisons of venomous animals, are chemically pure toxic molecules with more or less specific actions on biological systems [1-3]. A large number of toxins have been isolat‐ ed and characterized from snake venoms and snake venoms repertoire typically contain from 30 to over 100 protein toxins. Some of these molecules present enzymatic activities, whereas several others are non-enzymatic proteins and polypeptides. The most frequent en‐ zymes in snake venoms are phospholipases A2, serine proteinases, metalloproteinases, ace‐ tylcholinesterases, L-amino acid oxidases, nucleotidases and hyaluronidases. Higher catalytic efficiency, heat stability and resistance to proteolysis as well as abundance of snake venom enzymes provide them attractive models for biotechnologists, pharmacologists and biochemists [3-4]. Scorpion toxins are classified according to their structure, mode of action,

© 2013 Fernandes-Pedrosa et al.; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 Fernandes-Pedrosa et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

are highly undesirable. Persistently high blood pressure could cause or accelerate multiple pathological conditions such as organ (heart and kidney) failure and thrombosis events (heart attack and stroke) [14]. So, it is important to lower the blood pressure of high-rick pa‐ tients through use of specific anti-hypertensive agents, and in this scenario, snake venom toxins has been shown to be promising sources [14-15]. This is because it has long been not‐ ed that some snake venoms drastically lower the blood pressure in human victims and ex‐ perimental animals [15]. The first successful example of developing a drug from an isolated toxin was the anti-hypertensive agent Capoten® (captopril), an angiotensin-converting en‐ zyme (ACE) inhibitor modeled from a venom peptide isolated from *Bothrops jararaca* venom [16]. These bradykinin-potentiating peptides (BPPs) are venom components which inhibits the breakdown of the endogenous vasodilator bradykinin while also inhibiting the synthesis of the endogenous vasoconstrictor angiotensin II, leading to a reduction in blood pressure [15]. BPPs have also been identified in *Crotalus durissus terrificus* venom [17]. Snake venom represents one of the major sources of exogenous natriuretic peptides (NPs) [18]. The first venom NP was identified from *Dendroaspis angusticeps* snake venom and was named *Den‐ droaspis* natriuretic peptide (DNP) [19]. Other venom NPs were also reported in various snake species, such as *Micrurus corallinus* [20], *B. jararaca* [4], *Trimeresurus flavoviridis*, *Trimer‐ esurus gramineus*, *Agkistrodon halys blomhoffii* [21], *Pseudocerastes persicus* [22], *Crotalus durissus cascavella* [23], *Bungarus flaviceps* [24], among others. L-type Ca2+-channels blockers identified in snake venoms include calciseptine [25] and FS2 toxins [26] from *Dendroaspis polylepis poly‐ lepis*, C10S2C2 from *D. angusticeps* [27], S4C8 from *Dendroaspis jamesoni kaimosae* [28] and stej‐

Toxins from Venomous Animals: Gene Cloning, Protein Expression and Biotechnological Applications

http://dx.doi.org/10.5772/52380

25

Desintegrins are a family of cysteine-rich low molecular weight proteins that inhibits vari‐ ous integrins and that usually contain the integrin-binding RGD motif, that binds the GPIIa/ IIIb receptor in platelets, thus prevents the binding of fibrinogen to the receptor and conse‐ quently platelet aggregation [13]. Two drugs, tirofiban (Aggrastat®) and eptifibatide (Integ‐ rillin®) were designed based on snake venom disintegrins and are avaliable in the market as antiplatelet agents, approved for preventing and treating thrombotic complications in pa‐ tients undergoing percutaneous coronay intervention and in patients with acute cornonary sydrome [30-31]. Tirofiban has a non-peptide structure mimicking the RDG motif of the dis‐ integrin echistatin from *Echis carinatus* [30]. Eptifibatide is a cyclic peptide based on the KGD motif of barbourin from *Sisturus miliaris barbouri* snake [31]. Recently, leucurogin, a new re‐ combinant disintegrin was cloned from *Bothrops leucurus*, being a potent agent upon platelet aggregation [32]. Thrombin-like enzymes (TLEs) are proteases reported from many different crotalid, viperid and colubrid snakes that share some functional similarity with thrombin [13]. TLEs are not inactivated by heparin-antithrombin III complex (the physiological inhibi‐ tor of thrombin), and, differently to thrombin, they are not able to activate FXIII (the enzyme that covalently cross-links fibrin monomer to form insoluble clots). These are interesting properties, because although being procoagulants *in vitro*, TLEs have the clinical results of being anti-coagulants, by the depletion of plasma level of fibrinogen, and the clots formed are easily soluble and removed from the body. At same time, thrombolysis is enhanced by

nihagin, a metalloproteinase from *Trimeresurus stejnegeri* [29].

**2.2. Toxins acting on hemostasis**

and binding site on different channels or channel subtypes. The venom is constituted by mucopolysaccharides, hyaluronidases, phospholipases, serotonins, histamines, enzyme in‐ hibitors, antimicrobials and proteins namely neurotoxic peptides. Scorpion peptides presents specificity and high affinity and have been used as pharmacological tools to charac‐ terize various receptor proteins involved in normal ion channel functionating, as abnormal channel functionating in cases of diseases. The venoms can be characterized by identifica‐ tion of peptide toxins analysis of the structure of the toxins and also have proven to be among the most and selective antagonists available for voltage-gated channels permeable to K+ , Na+ , and Ca2+. The neurotoxic peptides and small proteins lead to dysfunction and pro‐ voke pathophysiological actions, such as membrane destabilization, blocking of the central, and peripheral nervous systems or alteration of smooth or skeletal muscle activity [5-8]. Spi‐ der venoms are complex mixtures of biologically active compounds of different chemical na‐ ture, from salts to peptides and proteins. Specificity of action of some spider toxins is unique along with high toxicity for insects, they can be absolutely harmless for members of other taxons, and this could be essential for investigation of insecticides. Several spider toxins have been identified and characterized biochemically. These include mainly ribonucleotide phosphohydrolase, hyaluronidases, serine proteases, metalloproteases, insecticidal peptides and phospholipases D [9-10]. Venoms from toads and frogs have been extensively isolated and characterized showing molecules endowed with antimicrobial and/or cytotoxic activi‐ ties [11]. Studies involving the molecular repertoire of the venom of bees and wasps have revealed the partial isolation, characterization and biological activity assays of histamines, dopamines, kinins, phospholipases and hyaluronidases. The venom of caterpillars has been partially characterized and contains mainly ester hydrolases, phospholipases and proteases [12]. The purpose of this chapter is to present the main toxins isolated and characterized from the venom of venomous animals, focusing on their biotechnological and pharmacolog‐ ical applications.
